Concepedia

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

Carole Soussain, Sylvain Choquet, Marie Blonski, Delphine Leclercq, Caroline Houillier, Keyvan Rezaï, Fontanet Bijou, Roch Houot, E. Boyle, Rémy Gressin,

European Journal of Cancer · 2019 · 318 citations · 22 references

DOIFull text

Open access

Concepts

References

22

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Christine P. Hans · Blood · 2003 · 4.3K citations · Full text

, , +16

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman et al. · Journal of Clinical Oncology · 2012 · 1.1K citations · Full text

, , +17

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Wyndham H. Wilson, Ryan M. Young, Roland Schmitz et al. · Nature Medicine · 2015 · 1.1K citations · Full text

, , +13

Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

Lauren E. Abrey, Tracy T. Batchelor, Andrés J.M. Ferreri et al. · Journal of Clinical Oncology · 2005 · 906 citations

, , +17

Targetable genetic features of primary testicular and primary central nervous system lymphomas

Bjoern Chapuy, Margaretha G.M. Roemer, Chip Stewart et al. · Blood · 2015 · 599 citations · Full text

, , +16